Search Results - "DiCioccio, Albert Thomas"

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors

    A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors by Chiorean, Elena Gabriela, LoRusso, Patricia, Strother, Robert Matthew, Diamond, Jennifer R, Younger, Anne, Messersmith, Wells A, Adriaens, Lieve, Liu, Liming, Kao, Richard J, DiCioccio, Albert Thomas, Kostic, Ana, Leek, Russell, Harris, Adrian, Jimeno, Antonio

    Published in Clinical cancer research (15-06-2015)
    “…Enoticumab (REGN421) is a fully human IgG1 monoclonal antibody that binds human Dll4 and disrupts Notch-mediated signaling. The main objectives of this trial…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  2. 2
    Population Pharmacokinetics of Fasinumab in Healthy Volunteers and Patients With Pain Due to Osteoarthritis of the Knee or Hip

    Population Pharmacokinetics of Fasinumab in Healthy Volunteers and Patients With Pain Due to Osteoarthritis of the Knee or Hip by Lin, Kuan‐Ju, Turner, Kenneth C., Hassan, Hazem E., Harnisch, Lutz O., Davis, John D., DiCioccio, Albert Thomas

    Published in Clinical pharmacology in drug development (01-06-2024)
    “…Osteoarthritis (OA) pain management options are currently limited. Fasinumab, an anti‐nerve growth factor monoclonal antibody, has been investigated in healthy…”
    Get full text
    Journal Article
    Save to List
    Saved in:

Search Tools: